All In Biotech

Drug Trial Radar · NCT07070440

DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)

A Phase 1/2, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)

Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Jul 16, 2025

Primary completion

Jun 2027

Study completion Dec 2028

Sponsor

Lead sponsor
Dizal PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jul 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to evaluate safety and antitumor activity of DZD6008 combination therapy in patients with advanced Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) mutations.

Conditions

  • Non Small Cell Lung Cancer

Interventions

  • DZD6008Drug

    DZD6008 was administered orally at 40/60/90 mg QD.

  • PemetrexedDrug

    Pemetrexed 500 mg/m2, every 3 weeks, intravenous infusion.

  • CarboplatinDrug

    Carboplatin AUC 5 mg/mL/min, every 3 weeks, intravenous infusion.

  • DocetaxelDrug

    Docetaxel 75 mg/m2, every 3 weeks, intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Dose-limiting Toxicities (DLTs)Time frame: 21 days after the first dosing
  2. Number of participants with Adverse events (AEs)/Serious adverse events (SAEs)Time frame: Through the study completion, an average of around 1 year.
  3. Objective Response Rate (ORR) as assessed by investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1Time frame: Through the study completion, an average of around 1 year.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Chest Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.